Business
BioAtla Highlighted Clinical Program and Pipeline Updates at Virtual R&D Day
Clinical benefit observed among non-small cell lung cancer (NSCLC) patients harboring mutant KRAS (mKRAS) variants in the Phase 2 mecbotamab vedotin
About this update from Bioatla, Inc.
[{"type":"text","content":"Clinical benefit observed among non-small cell lung cancer (NSCLC) patients harboring mutant KRAS (mKRAS) variants in the Phase 2 mecbotamab vedotin (CAB-AXL-ADC) study; AXL tumoral expression highly associated with multiple mKRAS variants Evalstotug (CAB-CTLA-4 antibody) as a monotherapy and in combination with PD-1 continues to provide promising anti-tumor activity with a differentiated safety profile associated with a low incidence of immune-related adverse events SAN DIEGO, July 25, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today hosted a virtual R&D Day on its novel conditionally and reversibly active antibody drug conjugate mecbotamab vedotin, targeting the receptor tyrosine kinase AXL, and its antibody targeting CTLA-4, evalstotug. The R&D Day also featured renowned key opinion leaders, Dr. Edwin Yau, Dr. Omid Hamid and Dr. Ankit Mangla. “It is promising to see confirmed responses following mecbotamab vedotin treatment among heavily pretreated patients with tumors expressing KRAS mutations, including in a patient previously treated with a KRAS inhibitor,” said Dr. Yau. “Now that we are administering evalstotug doses that exceed 10 mg/kg equivalent of marketed CTLA-4 products in combination with PD-1 antibody, I continue to be gratified to observe such a low incidence and severity of immune related adverse events,” said Dr. Hamid. “Every one of my patients who has received evalstotug has experienced clinical benefit, including an advanced melanoma patient who achieved no evidence of disease, which I consider a clinical complete response,” said Dr. Mangla. Details of the presentation and a replay of the event will be available on BioAtla’s “Events and Presentations” website after the event. Key R&D Day Topics and Highlights: Phase 2 Trial of mecbotamab vedotin, CAB-AXL-ADC, in NSCLC (NCT04681131) Additional expansion cohort completed evaluating AXL expression, dose and genotypeSubgroup results: AXL expression ≥1% correlated with clinical benefit in heavily pretreated patients with a median three prior lines of therapyInitial clinical benefit observed in both Q2W and 2Q3W dosing regimensInitial clinical benefit with multiple confirmed responses ...